Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German-Austrian diabetes registry.
Adult
Humans
Aged
Cholesterol, LDL
Proprotein Convertase 9
Diabetes Mellitus, Type 1
/ drug therapy
Diabetes Mellitus, Type 2
/ complications
Austria
/ epidemiology
Goals
Cholesterol
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ therapeutic use
Ezetimibe
/ therapeutic use
Atherosclerosis
Registries
Fibric Acids
Anticholesteremic Agents
/ therapeutic use
Dyslipidemias
/ therapy
database research
lipid-lowering therapy
real-world evidence
type 1 diabetes
type 2 diabetes
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
revised:
11
08
2023
received:
12
06
2023
accepted:
17
08
2023
medline:
13
11
2023
pubmed:
11
9
2023
entrez:
11
9
2023
Statut:
ppublish
Résumé
To assess the implementation of the 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guideline recommendations for lipid-lowering therapies among more than 30 000 patients with type 1 diabetes (T1D) and type 2 diabetes (T2D) in a German and Austrian registry from 2020 to 2022. Registry data from 2020 and 2021 of 32 170 adult patients (8314 patients with T1D and 23 856 with T2D) were stratified according to the 2019 ESC/EAS risk categories, and guideline-based low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) goal attainment was analysed. In patients with T1D (median age 38.35 [20.51-57.13] years), overall statin use was 19.3%, ezetimibe use was 2.2% and the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors or fibrates was less than 1%. In patients with T2D (median age 68.76 [58.86-78.39] years), 45.7% received statins, 3.4% received ezetimibe, and fibrates and PCSK9 inhibitors were used by 1% and 0.1%, respectively. Among patients with T1D, 6.16% reached their risk-based recommended LDL-C goal of less than 55 mg/dL (very high risk), 10.97% of less than 70 mg/dL (high risk), and 69.50% of less than 100 mg/dL (moderate risk), respectively. In patients with T2D, 11.81% reached their risk-based goal of LDL-C less than 55 mg/dL, 16.25% of less than 70 mg/dL, and 51.33% of less than 100 mg/dL. Non-HDL-C goals were reached more often, with 15.3%, 25.52% and 91.61% in patients with T1D and 18.56%, 17.96% and 82.30% in patients with T2D for very high, high and moderate risk, respectively. Approximately 2 years after publication of the guidelines, LDL-C and non-HDL-C goal attainment was rarely achieved in patients with T1D and T2D with a high or very high cardiovascular risk.
Substances chimiques
lipoprotein cholesterol
0
Cholesterol, LDL
0
PCSK9 protein, human
EC 3.4.21.-
Proprotein Convertase 9
EC 3.4.21.-
Cholesterol
97C5T2UQ7J
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Ezetimibe
EOR26LQQ24
Fibric Acids
0
Anticholesteremic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3700-3708Informations de copyright
© 2023 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
Boren J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2020;41(24):2313-2330.
Trialists CT. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397-1405.
Ridker PM. LDL cholesterol: controversies and future therapeutic directions. Lancet. 2014;384(9943):607-617.
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European atherosclerosis society (EAS). Eur Heart J. 2019;41(1):111-188. doi:10.1093/eurheartj/ehz455
Ray KK, Reeskamp LF, Laufs U, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022;43(8):830-833. doi:10.1093/eurheartj/ehab718
Banach M, Penson PE, Vrablik M, et al. ACS EuroPath Central & South European Countries Project Optimal use of lipid-lowering therapy after acute coronary syndromes: a position paper endorsed by the international lipid expert panel (ILEP). Pharmacol Res. 2021;166:105499. doi:10.1016/j.phrs.2021.105499
Ray KK, Haq I, Bilitou A, et al. SANTORINI study investigators treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health - Europe. 2023;29. doi:10.1016/j.lanepe.2023.100624
Khunti K, Danese MD, Kutikova L, et al. Association of a combined measure of adherence and treatment intensity with cardiovascular outcomes in patients with atherosclerosis or other cardiovascular risk factors treated with statins and/or ezetimibe. JAMA Netw Open. 2018;1(8):e185554.
Bytyçi I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43(34):3213-3223. doi:10.1093/eurheartj/ehac015
Bohn B, Kerner W, Seufert J, et al. Trend of antihyperglycaemic therapy and glycaemic control in 184,864 adults with type 1 or 2 diabetes between 2002 and 2014: analysis of real-life data from the DPV registry from Germany and Austria. Diabetes Res Clin Pract. 2016;115:31-38. doi:10.1016/j.diabres.2016.03.008
Danne T, Kaltheuner M, Koch A, et al. “DIabetes Versorgungs-Evaluation” (DIVE) - a national quality assurance initiative at physicians providing care for patients with diabetes. Dtsch Med Wochenschr. 2013;138(18):934-939. doi:10.1055/s-0033-1343144
Group TDR. Feasibility of centralized measurements of glycated hemoglobin in the diabetes control and complications trial: a multicenter study. The DCCT research Group. Clin Chem. 1987;33(12):2267-2271.
Group DR. Diabetes control and complications trial (DCCT): update. Diabetes Care. 1990;13(4):427-433. doi:10.2337/diacare.13.4.427
Ray KK, Molemans B, Schoonen WM, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2020;28(11):1279-1289. doi:10.1093/eurjpc/zwaa047
Kotseva K, De Backer G, De Bacquer D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26(8):824-835.
De Backer G, Jankowski P, Kotseva K, et al. Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135-146.
Schubert J, Lindahl B, Melhus H, et al. Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. Eur Heart J. 2021;42(3):243-252.
Vallejo-Vaz AJ, Stevens CA, Lyons AR, et al. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS familial Hypercholesterolaemia studies collaboration (FHSC). Lancet. 2021;398:1713-1725.
Virani SS, Kennedy KF, Akeroyd JM, et al. Variation in lipid-lowering therapy use in patients with low-density lipoprotein cholesterol≥ 190 mg/dL: insights from the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence registry. Circ Cardiovasc Qual Outcomes. 2018;11(5):e004652.
McManus R, Mant J, Meulendijks C, et al. Comparison of estimates and calculations of risk of coronary heart disease by doctors and nurses using different calculation tools in general practice: cross sectional study. BMJ. 2002;324(7335):459-464.
Allan GM, Nouri F, Korownyk C, Kolber MR, Vandermeer B, McCormack J. Agreement among cardiovascular disease risk calculators. Circulation. 2013;127(19):1948-1956.
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;42(34):3227-3337. doi:10.1093/eurheartj/ehab484
Group S-DW, Collaboration tECR. SCORE2-diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J. 2023;44:2544-2556. doi:10.1093/eurheartj/ehad260
Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011;171(9):814-822.
Fischer F, Lange K, Klose K, Greiner W, Kraemer A. Barriers and strategies in guideline implementation-a scoping review. MDPI. 2016;4:36.
Brandts J, Bray S, Villa G, et al. Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study. Lancet Reg Health - Europe. 2023;31:100665. doi:10.1016/j.lanepe.2023.100665
Ray KK. Changing the paradigm for post-MI cholesterol lowering from intensive statin monotherapy towards intensive lipid-lowering regimens and individualized care. Eur Heart J. 2021;42(3):253-256.
Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol. 2020;21(4):464-474. doi:10.1177/2047487314525531
Gupta A, Thompson D, Whitehouse A, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian cardiac outcomes trial-lipid-lowering arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017;389(10088):2473-2481.
Reith C, Baigent C, Blackwell L, et al. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400(10355):832-845.
Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of Bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022-1032. doi:10.1056/NEJMoa1803917
Laufs U, Banach M, Mancini GBJ, et al. Efficacy and safety of Bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7):e011662. doi:10.1161/JAHA.118.011662
Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195-203. doi:10.1016/j.atherosclerosis.2018.06.002
Guglielmi V, Bellia A, Pecchioli S, et al. Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: a real-world evidence study in primary care. Atherosclerosis. 2017;263:36-41.
Zafrir B, Egbaria A, Stein N, Elis A, Saliba W. PCSK9 inhibition in clinical practice: treatment patterns and attainment of lipid goals in a large health maintenance organization. J Clin Lipidol. 2021;15(1):202-211. e2.
Wei L, Wang J, Thompson P, Wong S, Struthers A, MacDonald T. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart. 2002;88(3):229-233.
Bangalore S, Breazna A, DeMicco DA, Wun CC, Messerli FH, TNT Steering Committee and Investigators. Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial. J Am Coll Cardiol. 2015;65(15):1539-1548.
Brandts J, Ray KK. Low density lipoprotein cholesterol-lowering strategies and population health: time to move to a cumulative exposure model. Circulation. 2020;141(11):873-876.
Banach M, Surma S, Reiner Z, et al. Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022). Cardiovasc Diabetol. 2022;21(1):263. doi:10.1186/s12933-022-01684-5
Gitt AK, Sonntag F, Jannowitz C, et al. Better lipid target achievement for secondary prevention through disease management programs for diabetes mellitus and coronary heart disease in clinical practice in Germany. Curr Med Res Opin. 2016;32(3):417-426. doi:10.1185/03007995.2015.1120715